retatrutide type 2 diabetes trial 2024 produces up to 30.3% weight loss in Phase 3 Summary of the highest percent

Executive Summary GLP-1RA (Glucagon-like peptide-1 receptor agonist) drugs that help regulate blood sugar levels have been around for close to 20 years and are primarily used in diabetes treatment

Q3: What are the side effects of tesamorelin

But no need to flip out

From a pharmacological safety perspective, the adverse effect profile of retatrutide based on Phase 1 and Phase 2 clinical trial data (including the NEJM 2023 Phase 2 trial) includes: Gastrointestinal effects: Nausea, vomiting, diarrhoea, and constipation (the most commonly reported side effects in trial participants) Injection site reactions: Redness, swelling, or discomfort at the injection site Cardiovascular effects: Increases in heart rate have been observed in trial participants [21] [22] Hypoglycaemia: Particularly relevant in individuals with diabetes or those taking insulin, sulfonylureas, or other glucose-lowering agents Potential thyroid effects: GLP-1 receptor agonists have been associated with thyroid C-cell changes in rodent studies